IP Library Granted Patent US 7,053,229
Granted Patent B2
US 7,053,229 · App. 10/416,028 · Granted May 30, 2006

Process for the production of 4-(17α-alkoxymethyl-17β-substituted 3-oxoestra-4,9-dien-11β-yl) benzaldehyde-(1E)-oxime derivatives

Assignee: Schering AG
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,053,229
App. No.
10/416,028
Granted
May 30, 2006
Kind
B2
Abstract

This invention relates to a process for the production of 4-(17α-alkoxymethyl-17β-substituted-3-oxoestra-4,9-dien-11β-yl)benzaldehyde-(1E)-oxime derivatives of general formula (I) in which R means an amino group, an O—C 1-7 -alkyl- or O-aryl radical, an S—C 1-7 -alkyl- or S-aryl radical, an NH—C 1-7 -alkyl- or NH-aryl radical or an N-di-C 1-7 -alkyl radical, and R 1 means a hydrogen atom or a C 1-6 -alkyl radical, which yields the target compounds of formula (I) with high yield and selectivity.

Claims (38)

1. A process for preparing a 4-(17α-alkoxymethyl-17β-substituted-3-oxoestra-4,9-dien-11β-yl)benzaldehyde-(1E)-oxime compound of formula (I)

in which

R means an amino group, an O—C 1-7 -alkyl- or O-aryl radical, an S—C 1-7 -alkyl- or S-aryl radical, an NH—C 1-7 -alkyl- or NH-aryl radical or an N-di-C 1-7 -alkyl radical,

R 1 means a hydrogen atom or a C 1-6 -alkyl radical,

R 2 means a C 1-4 -alkyl radical, and

R 3 means a C 1-6 -alkyl radical,

comprising reacting a benzadoxime compound of formula (II)

in which

R 1 , R 2 and R 3 have the meanings provided above,

with chloroformic acid trichloromethyl ester or phosgene in an inert solvent in the presence of a tert-amine compound at a temperature of −35 to +30° C. to form the chloroformic acid compound of formula (III),

in which

R 1 , R 2 and R 3 have the meanings provided above,

and reacting the chloroformic acid compound of formula (III) with a C 1-7 -alkyl- or aryl alcohol, C 1-7 -alkyl- or aryl thioalcohol or C 1-7 -alkyl- or arylamine or a di-C 1-7 -alkylamine compound to form a 4-(17α-alkoxymethyl-17β-substituted-3-oxoestra-4,9-dien-11β-yl)benzaldehyde-(1E)oxime compound of formula (I).

2. A process according to claim 1 , wherein R 1 means a C 1-3 -alkyl radical.

3. A process according to claim 1 , wherein R 2 means a C 1-3 -alkyl radical.

4. A process according to claim 1 , wherein R 3 means a C 1-3 -alkyl radical.

5. A process according to claim 1 , wherein R means an amino-, methoxy-, ethoxy-, phenoxy-, methylthio-, ethylthio-, NH-methyl-, NH-ethyl-, NH-propyl-, NH-phenyl- or NH-tetrahydropyranyl group.

6. A process according to claim 1 , wherein the following compound of formula (I) is prepared:

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(ethyloxy)carbonyl]oxime,

4-[17β-Hydroxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[O-(ethyloxy)carbonyl]oxime,

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(methoxy)carbonyl]oxime,

4-[17β-Hydroxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(methoxy)carbonyl]oxime,

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(ethylamino)carbonyl]oxime,

4-[17β-Hydroxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(ethylamino)carbonyl]oxime,

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(ethylthio)carbonyl]oxime,

4-[17β-Hydroxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(ethylthio)carbonyl]oxime,

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(methylthio)carbonyl]oxime,

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(phenyloxy)carbonyl]oxime,

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(tetrahydropyranylamino)carbonyl]oxime,

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(amino)carbonyl]oxime, or

4-[17β-Methoxy-17α-(methoxymethyl)-3-oxoestra-4,9-dien-11β-yl]benzaldehyde-1E-[(O-(propylamino)carbonyl]oxime.

7. A process according to claim 1 , wherein the tert-amine compound is triethylamine.

8. A process according so claim 1 , wherein R 1 means a methyl group.

9. A process according to claim 1 , wherein R 2 means a methyl group.

10. A process according go claim 1 , wherein R 3 means a methyl group.

11. A process according to claim 1 , wherein the inert solvent is an aromatic solvent, toluene, ether, tetrahydrofuran or methyl-tert-butyl ether.

12. A process according to claim 1 , wherein the benzadoxime compound of formula (II) is reacted with chloroformic acid trichloromethyl ester or phosgene at a temperature −35° C.

13. A process according to claim 1 , further comprising isolating and purifying a compound of formula (I) by recrsystalization or chromatography or preparative layer chromatography.

Assignments (4)
CHANGE OF NAME Recorded May 17, 2013
From: BAYER PHARMA AKTIENGESELLSCHAFT
To: BAYER INTELLECTUAL PROPERTY GMBH
Reel/Frame 030434/0232 →
CHANGE OF NAME Recorded May 17, 2013
From: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
To: BAYER PHARMA AKTIENGESELLSCHAFT
Reel/Frame 030442/0400 →
CHANGE OF NAME Recorded May 17, 2013
From: SCHERING AG
To: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT
Reel/Frame 030452/0021 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 20, 2003
From: SCHUBERT, GERD; RING, SVEN
To: SCHERING AG
Reel/Frame 014643/0672 →
Priority Claims (1)
DE 100 56 677 · Nov 10, 2000 · national
Continuity (1)
Related Publication 20040059141A1 · Mar 25, 2004